期刊文献+

艾塞那肽对2型糖尿病肥胖患者血糖和体重的控制效果 被引量:1

下载PDF
导出
摘要 目的:观察艾塞那肽对2型糖尿病肥胖患者血糖和体重的控制效果。方法:选取本院住院治疗的体重指数>24kg/m2的2型糖尿病患者12例,既往使用多种口服降糖药及阿卡波糖片,餐后血糖控制不佳者,改用艾塞那肽注射液治疗,8周后比较治疗前后患者的空腹血糖、餐后2h血糖、体重指数、HbA1c的控制情况。结果:与治疗前比较,患者应用艾塞那肽治疗后的空腹血糖、餐后2h血糖、糖化血红蛋白值有所降低,比较差异有统计学意义(P<0.05),患者体重有不同程度下降,由于观察时间较短,差异无统计学意义(P>0.05)。结论:艾塞那肽能够更加有效控制2型糖尿病肥胖患者的血糖升高和体重增加。
出处 《中国医学创新》 CAS 2012年第27期112-113,共2页 Medical Innovation of China
  • 相关文献

参考文献8

  • 1Riddle M C, Rosenstoek J; Gerieh J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to or altherapy of type 2 diabetic patients[J]. Diabetes Care, 2003, 26(17):3080- 3086.
  • 2Klein S, Sheard N F, Pi-Sunyer X. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition[J]. Diabetes Care, 2004, 27(20):2067-2073.
  • 3韩文彪.艾塞那肽治疗2型糖尿病疗效的初步观察[J].青海大学学报,2011,10(18):22-23.
  • 4陈刚.艾塞那肽治疗超重和肥胖2型糖尿病32例疗效观察[J].中外医学研究,2011,9(35):150-151. 被引量:3
  • 5骆天红,郑以漫.胰升糖素样肽1对胰岛β细胞作用的研究进展[J].中华内分泌代谢杂志,2008,24(6). 被引量:38
  • 6付鸿玉,刘冰梅,刘立波.艾塞那肽治疗2型糖尿病20例临床观察[J].中国医疗前沿,2011,6(18):32-32. 被引量:6
  • 7Drucker D J. Enhancing incretin action for the treatment of type 2 diabetes[J]. Diabetes Care, 2003, 26(10):2929-2940.
  • 8DeFronzo R A, Ratner R E, Han J, et al. Effects of exenatide (exendin-4) on glyccmic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes[J]. Diabetes Care, 2005, 28(12):1092-1100.

二级参考文献40

  • 1王育璠,彭永德.胰高血糖素样肽-1——2型糖尿病治疗的新策略[J].世界临床药物,2004,25(12):718-721. 被引量:4
  • 2刘惠侠,曾璐琳.新型降糖药exenatide的研究进展[J].世界临床药物,2005,26(11):691-694. 被引量:8
  • 3Dov A, Abramovitch E, Warwar N, et al. Diminished phospho-diesterase-SB potentiates biphasic insulin response to glucose. Endocrinology, 2008,149:741-748.
  • 4Yaekura K, Julyan R, Wicksteed BL, et al. Insulin secretory deficiency and glucose intolerance in Rab3A null mice. J Biol Chem, 2003,278,9715-9721.
  • 5Doyte M, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev, 2003,55:105-131.
  • 6Park H, Dong X, Fisher TL, et al. Exendin-4 uses Irs 2 signaling to mediate pancreatic β cell growth and function. J Biol Chem, 2006, 281:1159-1168.
  • 7Knoch KP, Meisteffeld R, Kersting S, et al. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells. Cell Metab, 2006,3:123-134.
  • 8Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass. Diabetes, 2006,55 : 1190-1196.
  • 9De Heer J, Hoist JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes, 2007,56:438-443.
  • 10MacDonald PE, Wheeler MB. Vohage-dependent K^+ channels in pancreatic β cells: role, regulation and potential as therapeutic targets. Diabetologia, 2003,46 : 1046-1062.

共引文献44

同被引文献11

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部